Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes SocietyOpen in a New Window

LYON, France--(BUSINESS WIRE)--POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that it will be featured as a presenting company at the Jefferies 2019 Global Healthcare Conference and the JMP Securities Life Sciences Conference. In addition, Imeglimin will be discussed during a symposium at the 62nd Annual Meeti

 

Imago BioSciences to Present First Clinical Data for IMG-7289 At 24th Congress of the European Hematology AssociationOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/EHA24?src=hash" target="_blank"gt;#EHA24lt;/agt;--Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that an abstract describing clinical data regarding their lysine-specific demethylase (LSD1) inhibitor has been selected for an oral presentation at the 24th Congress of the European Hematology Association (EHA) to be held in Amsterdam, The Netherlands from June 13-16, 2019. The abstract was published on the EHA website. Title: A

 

Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell ActivationOpen in a New Window

SAN LEANDRO, Calif.--(BUSINESS WIRE)--Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of data from its FIERCE-22 trial where vofatamab, the company’s lead therapeutic stimulates an increase in immune cell activation in patients with metastatic bladder cancer. The data is being presented in an oral and poster presentation at the 2019 American Association for Cancer Research (AACR) Bladder Cancer: Transforming the Field Specia

 

Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Previously-Treated Patients with Metastatic Triple-Negative Breast CancerOpen in a New Window

KENILWORTH, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;--Merck Provides Update on Phase 3 KEYNOTE-119 Study of KEYTRUDA® Monotherapy in Previously-Treated Patients w/ Metastatic Triple-Negative Breast Cancer

 

DABRA Laser to be Presented as a Frontline Therapy for CLI at the 2019 SCAI Scientific SessionsOpen in a New Window

CARLSBAD, Calif.--(BUSINESS WIRE)--Ra Medical Systems, Inc. (NYSE: RMED) today announced that Dr. Mohammad Ansari will present DABRA as a treatment for critical limb ischemia (CLI) during a scientific case review May 21 at the SCAI annual meeting in Las Vegas. “The unique DABRA catheter and laser system is a highly effective frontline therapy for peripheral artery disease (PAD) that provides my patients excellent results, shorter rehabilitation time, and shorter hospitalizations,” said Dr. Ansa

 

RMS Medical Products to Present at 9th Annual LD Micro InvitationalOpen in a New Window

CHESTER, N.Y.--(BUSINESS WIRE)--Repro Med Systems, Inc. dba RMS Medical Products (OTCQX: REPR) (“RMS Medical”) today announced that Executive Chairman Dan Goldberger is scheduled to present at the 9th Annual LD Micro Invitational on June 5, 2019. The event is being held at the Luxe Sunset Hotel in Bel-Air, California. RMS Medical’s presentation will take place at 10:20 am Pacific Time. A copy of the slides will be available under the Investor Relations section of RMS Medical’s website: www.rmsm

 

Clovis Oncology Presents Patient-Centered Outcomes Data from Phase 3 ARIEL3 Study for Rubraca®▼ in Advanced Ovarian CancerOpen in a New Window

BOULDER, Colo.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24CLVS&src=ctag" target="_blank"gt;$CLVSlt;/agt;--Clovis Oncology, Inc. (NASDAQ: CLVS) today announced data demonstrating that patients with recurrent ovarian cancer who received Rubraca in the Phase 3 ARIEL3 study had longer periods of quality-adjusted time without clinically relevant symptoms as compared to patients who received placebo, and that Rubraca maintenance treatment continued to provide significant benefit in progression-free survival when weighted with patients’ perceptions of their wellbeing. The

 

Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial of OTX-TP for the Treatment of GlaucomaOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank"gt;$OCULlt;/agt; lt;a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank"gt;#OCUTXlt;/agt;--Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from the first pivotal Phase 3 clinical trial of OTX-TP, an intracanalicular insert that delivers a preservative-free formulation of the drug travoprost for the reduction of intraocular pressure (IOP) in patients with primary open-angle

 

Frelii Files Quarterly Report on Form 10-QOpen in a New Window

LEHI, Utah--(BUSINESS WIRE)--Frelii Inc. Filed its quarterly report on form 10-Q

 

Pioneering genomic medicine center at Children’s Mercy benefits from Black & Veatch fundraiserOpen in a New Window

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Black & Veatch today hosted the 23rd edition of its Charity Golf Tournament in support of Children’s Mercy. Proceeds from the tournament and company giving totaling $350,000 were donated to the renowned children’s hospital, part of a five-year pledge of $2.1 million made in 2015 to help expand services at the hospital’s Center for Pediatric Genomic Medicine. The annual golf event and company donations have now surpassed $4.1 million since its inception.

 

Galt Acquires Arrotek MedicalOpen in a New Window

GARLAND, Texas--(BUSINESS WIRE)--Galt Medical, a supplier of access products for interventional procedures, acquired Arrotek, a developer of catheter-based interventional devices.

 

Battelle-Led Team Wins DARPA Award to Develop Injectable, Bi-Directional Brain Computer InterfaceOpen in a New Window

COLUMBUS, Ohio--(BUSINESS WIRE)--Battelle has for years successfully demonstrated brain-computer interface (BCI) projects—just look at NeuroLife®, which has enabled a quadriplegic man to move his hand again using his thoughts. Now, the government’s forward-thinking Defense Advanced Research Projects Agency (DARPA) has awarded a contract to a Battelle-led team that pushes researchers into the realm of what was once considered science fiction. Imagine this: A soldier puts on a helmet and uses his

 

Former U.S. Secretary of Agriculture and Iowa Governor to Receive 2019 George Washington Carver AwardOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/BIOWC19?src=hash" target="_blank"gt;#BIOWC19lt;/agt;--BIO today announced that Tom Vilsack will receive the 12th annual George Washington Carver Award for Innovation in Industrial Biotechnology.

 

Second-Generation Blood Test for Irritable Bowel Syndrome (IBS) Validated as Providing Most Conclusive Diagnosis of Inclusion for IBSOpen in a New Window

SAN DIEGO--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/guthealth?src=hash" target="_blank"gt;#guthealthlt;/agt;--Gemelli Biotech, in partnership with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, announced new findings that validate a second-generation diagnostic blood test for irritable bowel syndrome (IBS) as the most accurate ever. Available commercially as ibs-smart™, the test could provide physicians with the most conclusive data currently attainable for ruling in IBS. Primarily applicable to patients with a diarrheal component to their sy

 

Donaldson Company Breaks Ground for New Material Research Center at its Corporate Headquarters in Bloomington, MinnesotaOpen in a New Window

MINNEAPOLIS--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24DCI&src=ctag" target="_blank"gt;$DCIlt;/agt; lt;a href="https://twitter.com/hashtag/earnings?src=hash" target="_blank"gt;#earningslt;/agt;--Donaldson breaks ground on new $15 million R&D facility at its global headquarters in Bloomington, MN.

 

Texas Signs Age-Restriction Law to Curb Teen Cough Medicine AbuseOpen in a New Window

WASHINGTON--(BUSINESS WIRE)--On May 17th, Texas Governor Greg Abbott signed into law an age-18 requirement for the purchase of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM), an ingredient which is abused by some teenagers to get high. Texas is the 19th state to prohibit the sale of OTC cough medicine to minors, joining other large states, including California, New York, and Florida. “For over a decade, OTC manufacturers have worked alongside anti-subst

 

Vedanta Biosciences Presents Positive Expanded Data from Phase 1a/1b Study of VE303 at Digestive Disease WeekOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vedanta Biosciences announced the presentation of expanded, long-term data from its Phase 1a/1b study of VE303, its lead product.

 

Motus GI Presents Positive Clinical Results from REDUCE Study Evaluating Pure-Vu® System in Hospitalized Colonoscopy Patients at Digestive Disease Week® 2019Open in a New Window

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, today announced it will present positive full clinical results from the Company’s REDUCE (“Reliable Endoscopic Diagnosis Utilizing Cleansing Enhancement”) study evaluating the Pure-Vu® System at Digestive Disease Week® 2019 (“DDW”). Vladimir Kushnir, M.D., Division of

 

Foley Hoag Secures Win for Dana-Farber Cancer Institute on Challenge to Inventorship of Groundbreaking Cancer Immunotherapy PatentsOpen in a New Window

BOSTON--(BUSINESS WIRE)--The U.S. District Court ruled in favor of Foley Hoag LLP’s client, Dana-Farber Cancer Institute, that Dana-Farber scientist, Gordon Freeman, PhD, and another scientist, Clive Wood, PhD, are co-inventors on a series of cancer immunotherapy patents previously issued to a Japanese researcher and Japanese drug company. The ruling directs that the patents be corrected to name Freeman and Wood as inventors. In her decision, Chief Judge Patti B. Saris wrote that “Dana-Farber h

 

Physicians’ Education Resource® to Host ASCO Direct™ Highlights in Kansas CityOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Breast?src=hash" target="_blank"gt;#Breastlt;/agt;--Physicians’ Education Resource® to Host ASCO Direct™ Highlights in Kansas City

 

Florida Research Institute & Echosens Present Research Studies at May 2019 Digestive Disease Week: Highlights Value of Non-Invasive Screening for Fatty Liver DiseaseOpen in a New Window

SAN DIEGO & WALTHAM, Mass.--(BUSINESS WIRE)--Echosens Presents Research Studies at May 2019 Digestive Disease Week: Highlights Value of Non-Invasive Screening for Fatty Liver Disease

 

Ayala Pharmaceuticals to Present at ASCO Annual Meeting on Investigational Drug AL101 in Adenoid Cystic Carcinoma and Triple Negative Breast CancerOpen in a New Window

REHOVOT, Israel & WILMINGTON, Del.---(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced updates on AL101, a pan-Notch inhibitor, that will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Il. The details of the poster presentations are as follows: Title: ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/met

 

PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing ProcessOpen in a New Window

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/INDstatus?src=hash" target="_blank"gt;#INDstatuslt;/agt;--PharmaCyte proceeding with GMP production of pancreatic cancer product after successful changes to manufacturing process.

 

MyHeritage Expands to Health; Launches New DNA Test Offering Powerful and Personalized Health Insights for ConsumersOpen in a New Window

TEL AVIV, Israel & LEHI, Utah--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/dna?src=hash" target="_blank"gt;#dnalt;/agt;--MyHeritage Expands to Health; Launches New DNA Test Offering Powerful and Personalized Health Insights for Consumers.

 

State of Nebraska Selects NIC Inc.’s RxGov® as Its New Prescription Drug Monitoring PlatformOpen in a New Window

OLATHE, Kan.--(BUSINESS WIRE)--NIC Inc. has been selected to provide its RxGov prescription drug monitoring platform to the State of Nebraska.

 

Cheetah Medical Showcases Fluid Management Education with Virtual Trainer App at the 2019 National Teaching Institute & Critical Care ExpositionOpen in a New Window

NEWTON, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/NTI2019?src=hash" target="_blank"gt;#NTI2019lt;/agt;--Cheetah Medical showcases fluid management education with Virtual Trainer app at the 2019 National Teaching Institute & Critical Care Exposition

 

Earth Networks Releases 2019 Hurricane OutlookOpen in a New Window

GERMANTOWN, Md.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/hurricane?src=hash" target="_blank"gt;#hurricanelt;/agt;--Earth Networks released its 2019 Atlantic Hurricane Season Outlook.

 

Categorical Response and Clinical Relevance as Assessed in a Phase III Study of HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the American Psychiatric Association 172nd Annual MeetingOpen in a New Window

MIAMI & JERSEY CITY, N.J.--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Ltd., announced today that secondary endpoint data from the pivotal Phase III study for HP-3070 (asenapine) transdermal drug delivery system (TDDS), an investigational product for the treatment of schizophrenia, will be featured as a poster presentation at the American Psychiatric Association (APA) 172nd Annual Meeting in San Francisco, May 18 – 22, 2019. This post

 

iSchemaView Launches RAPID UOpen in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/RAPIDai?src=hash" target="_blank"gt;#RAPIDailt;/agt;--iSchemaView, the worldwide leader in advanced imaging for stroke, has launched RAPID U, a training certification program for the RAPID platform.

 

Genomind Launches the Most Comprehensive Genetics-Based Mental Health Test Available, Genomind Professional PGx, to Help Clinicians Optimize Mental Health Medication DecisionsOpen in a New Window

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind – a leading mental health care company – today announced that its flagship pharmacogenetic product, Genomind Professional PGx™, is now available to patients through their health care providers. Genomind Professional PGx provides personalized analytics on patient-specific genetic markers. This information helps indicate which medications or other treatment options, for more than 11 mental health conditions, are better suited for a patient based on

 

Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 BillionOpen in a New Window

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vect

 

Zoetis to Participate in the Stifel 2019 Dental & Veterinary ConferenceOpen in a New Window

PARSIPPANY, N.J.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24ZTS&src=ctag" target="_blank"gt;$ZTSlt;/agt; lt;a href="https://twitter.com/hashtag/animalhealth?src=hash" target="_blank"gt;#animalhealthlt;/agt;--Zoetis Inc. will present at the Stifel 2019 Dental & Veterinary Conference on May 29 at 10:30 am ET.

 

DNAnexus Appoints David Fenstermacher as Vice President of Precision Medicine and Data SciencesOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bioinformatics?src=hash" target="_blank"gt;#bioinformaticslt;/agt;--DNAnexus Appoints David Fenstermacher as Vice President of Precision Medicine and Data Sciences

 

Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer DiagnosisOpen in a New Window

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis

 

Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical StudyOpen in a New Window

MENLO PARK, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/IOCombos360?src=hash" target="_blank"gt;#IOCombos360lt;/agt;--Personalis Enters into a Research Agreement with FLX Bio to Provide Comprehensive Tumor Immunogenomic Profiling for Clinical Study.

 

DNAnexus Appoints Scott Gibson as Chief Financial OfficerOpen in a New Window

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bioinformatics?src=hash" target="_blank"gt;#bioinformaticslt;/agt;--DNAnexus Appoints Scott Gibson as Chief Financial Officer

 

Savonix to Present at Upcoming Industry & Scientific ConferencesOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--Savonix to Present at Upcoming Industry & Scientific Conferences

 

National Cancer Institute Implements Cloud-First Data Protection with DruvaOpen in a New Window

SUNNYVALE, Calif.--(BUSINESS WIRE)--Druva, Inc., the leader in cloud data protection and management, today announced the National Cancer Institute (NCI), the federal government's primary agency addressing cancer research and treatment, is using Druva to replace its legacy hardware solutions for backup, restore and archiving of data. As the only FedRAMP certified data management solution, Druva’s unique technology ensures compliance with stringent government regulations and ease of management wi

 

FASENRA® (benralizumab) reduces oral corticosteroid use and maintains long-term efficacy and safety profile in severe eosinophilic asthmaOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Confere

 

Surescripts Expands White Coat Award to Recognize Health System, Pharmacy and EHR Leaders for Improving Prescription AccuracyOpen in a New Window

ARLINGTON, Va.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/EHR?src=hash" target="_blank"gt;#EHRlt;/agt;--Expanded award eligibility and updated criteria elevate industry leaders who make meaningful changes to enhance patient safety and healthcare delivery

 

Saama Challenges Analytics Industry to Guarantee Data Platforms to Help Accelerate Drug DevelopmentOpen in a New Window

CAMPBELL, Calif.--(BUSINESS WIRE)--Saama challenges analytics industry to guarantee data platforms to accelerate drug development; Saama Guarantee leads this call-to-action.

 

Oragenics, Inc. Provides Development Update of AG013 for Oral MucositisOpen in a New Window

TAMPA, Fla.--(BUSINESS WIRE)--Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound

 

Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of DermatologyOpen in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announces that data from key studies within its inflammation and autoimmunity portfolio will be presented at the 24th World Congress of Dermatology (WCD). This meeting will be held in Milan, Italy from June 10-15, 2019. Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Pha

 

KalVista Pharmaceuticals to Present Data at Upcoming Scientific ConferencesOpen in a New Window

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24KALV&src=ctag" target="_blank"gt;$KALVlt;/agt;--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced that data has been accepted for presentation at both the C1 Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary and European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. “We are excited to present

 

Kraig Biocraft Laboratories Takes Possession of Factory in VietnamOpen in a New Window

ANN ARBOR, Mich.--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24KBLB&src=ctag" target="_blank"gt;$KBLBlt;/agt; lt;a href="https://twitter.com/hashtag/KBLB?src=hash" target="_blank"gt;#KBLBlt;/agt;--Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that its subsidiary Prodigy Textiles has taken possession of its factory in Vietnam. The Company is now retrofitting the nearly 50,000 square foot facility to produce its game changing recombinant spider silk materials. Remodeling efforts are expected to be minimal and completed quickly. This facility was selected based on its optimal

 

PROCEPT BioRobotics® Announces New Clinical and Real-World Data Highlighting Effectiveness, Durability, Superior Safety and Reproducibility of Aquablation® Therapy for BPHOpen in a New Window

REDWOOD SHORES, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AUA19?src=hash" target="_blank"gt;#AUA19lt;/agt;--New clinical data presented at AUA 2019 position PROCEPT BioRobotics' Aquablation therapy as new standard of care for patients suffering from BPH.

 

Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)Open in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)

 

Intact Vascular to Sponsor Post-Angioplasty Dissection Symposium at 2019 New Cardiovascular Horizons ConferenceOpen in a New Window

WAYNE, Pa.--(BUSINESS WIRE)--Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured during a lunch symposium at the 2019 New Cardiovascular Horizons (NCVH) Conference, May 29th through 31st at The Roosevelt New Orleans in New Orleans, Louisiana. Recently FDA-approved for above-the-knee interventions, the Tack Endovascular System is a first-of-its-kind dissection repair device i

 

Corindus to Showcase CorPath® GRX Robotic System at EuroPCR 2019Open in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Clinique Pasteur is first European site to adopt latest CorPath GRX vascular robotic technology; Corindus to showcase technology at EuroPCR 2019

 

SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid TumorsOpen in a New Window

STAMFORD, Conn.--(BUSINESS WIRE)--SpringWorks Therapeutics Announces Initiation of Phase 3 Trial (DeFi) of Nirogacestat in Adult Patients with Desmoid Tumors

 

Magellan Rx Management’s Second Annual Employer Market Insights Report Highlights Market Dynamics and Opportunities for Traditional and Specialty DrugsOpen in a New Window

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Magellan Rx Management released its second Employer Market Insights Report, which highlights key areas of pharmacy trend and spend.

 

Inteliquet Signs Cooperative R&D Agreement (CRADA) with the National Cancer InstituteOpen in a New Window

MEMPHIS, Tenn.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/Cancer?src=hash" target="_blank"gt;#Cancerlt;/agt;--Inteliquet has entered into a Cooperative Research and Development Agreement with NCI.

 

Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019Open in a New Window

MENLO PARK, Calif.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/immuno19?src=hash" target="_blank"gt;#immuno19lt;/agt;--Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 2019: Advancing Precision Oncology Biomarker Discovery with ImmunoID NeXT.

 

New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During SurgeryOpen in a New Window

NEUCHATEL, Switzerland--(BUSINESS WIRE)--A new study evaluates the ability of Masimo SpHb® (noninvasive hemoglobin) to help clinicians estimate when to conduct invasive measurement.

 

About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect